ARTICLE | Finance
No ripple effect
Why a Japanese generics and biosimilars deal had no effect on Japan's biotechs
July 18, 2016 7:00 AM UTC
In contrast to big swings that occur on innovator partnering news, BioCentury's equal price-weighted index of 34 Japanese biotechs did precious little after Nichi-Iko Pharmaceutical Co. Ltd. (Tokyo:4541) announced plans to acquire fellow generics and biosimilars company Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) for $736 million in cash.
The index slipped 1% last week, which lagged the 9% gain by the broader Nikkei 225 index...